MA31293B1 - Utilisation d'un sel de cuivre masque ou enrobe pour le traitement d'une degenerescence maculaire - Google Patents

Utilisation d'un sel de cuivre masque ou enrobe pour le traitement d'une degenerescence maculaire

Info

Publication number
MA31293B1
MA31293B1 MA32248A MA32248A MA31293B1 MA 31293 B1 MA31293 B1 MA 31293B1 MA 32248 A MA32248 A MA 32248A MA 32248 A MA32248 A MA 32248A MA 31293 B1 MA31293 B1 MA 31293B1
Authority
MA
Morocco
Prior art keywords
mask
treatment
copper salt
macular degeneration
coated copper
Prior art date
Application number
MA32248A
Other languages
Arabic (ar)
English (en)
Inventor
Georg Ludwig Kis
Jacques Vandermander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39477329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31293(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07104792A external-priority patent/EP1974733A1/fr
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31293B1 publication Critical patent/MA31293B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/10—Coating with edible coatings, e.g. with oils or fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention porte sur un procédé servant à protéger de la décomposition des composés et/ou des compositions sensibles au cuivre, par utilisation d'un sel de cuivre masqué ou enrobé. De préférence, le cuivre est enrobé de gélatine, d'un liposome ou d'un mono- et d'un diglycéride.
MA32248A 2007-03-23 2009-10-02 Utilisation d'un sel de cuivre masque ou enrobe pour le traitement d'une degenerescence maculaire MA31293B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07104792A EP1974733A1 (fr) 2007-03-23 2007-03-23 Utilisation d' un sel de cuivre masqué ou enrobé pour le traitment de la dégénérescence maculaire
EP07111322 2007-06-28
PCT/EP2008/053283 WO2008116806A1 (fr) 2007-03-23 2008-03-19 Utilisation d'un sel de cuivre masqué ou enrobé pour le traitement d'une dégénérescence maculaire

Publications (1)

Publication Number Publication Date
MA31293B1 true MA31293B1 (fr) 2010-04-01

Family

ID=39477329

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32248A MA31293B1 (fr) 2007-03-23 2009-10-02 Utilisation d'un sel de cuivre masque ou enrobe pour le traitement d'une degenerescence maculaire

Country Status (26)

Country Link
US (1) US20080233182A1 (fr)
EP (1) EP2124973B1 (fr)
JP (1) JP2010521534A (fr)
KR (1) KR101688656B1 (fr)
AR (1) AR065791A1 (fr)
AU (1) AU2008231847B2 (fr)
BR (1) BRPI0809258B8 (fr)
CA (1) CA2681514C (fr)
CL (1) CL2008000804A1 (fr)
CO (1) CO6230993A2 (fr)
DK (1) DK2124973T3 (fr)
EC (1) ECSP099700A (fr)
ES (1) ES2542694T3 (fr)
GT (1) GT200900251A (fr)
IL (1) IL201109A (fr)
MA (1) MA31293B1 (fr)
MX (1) MX2009010244A (fr)
MY (1) MY164520A (fr)
NZ (1) NZ579852A (fr)
PE (1) PE20090186A1 (fr)
PL (1) PL2124973T3 (fr)
PT (1) PT2124973E (fr)
RU (1) RU2009139002A (fr)
TN (1) TN2009000387A1 (fr)
TW (1) TW200904456A (fr)
WO (1) WO2008116806A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12019500030A1 (en) * 2009-03-09 2020-02-10 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
KR101759255B1 (ko) 2015-09-18 2017-07-18 한국산업기술대학교산학협력단 무촉매 방식 가변경사각을 갖는 나노 구조물 성장 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2043487A1 (fr) * 1969-05-28 1971-02-19 Commissariat Energie Atomique
US5298237A (en) * 1992-01-24 1994-03-29 The Trustees Of Columbia University In The City Of New York Gel composition for reduction of gingival inflammation and retardation of dental plaque
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US20030004043A1 (en) * 2001-06-27 2003-01-02 Deola James A. Pivoting backrest for exercise apparatus
US20030104043A1 (en) * 2001-12-03 2003-06-05 Brown Beverly Ann Topical cream for alleviating spider veins
US20050249820A1 (en) * 2004-05-04 2005-11-10 Akorn, Inc. Nutritional supplement for the treatment and prevention of macular degeneration
WO2005110375A1 (fr) * 2004-05-08 2005-11-24 Paul Edward L Jr Supplément alimentaire pour le traitement des maladies oculaires
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
EP1614414A3 (fr) * 2004-07-09 2008-07-09 Robert Sabin Compositions contenant un composé de cuivre pour le traitement des maladies chez les mammifères
AU2005306320B2 (en) * 2004-11-19 2011-09-08 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

Also Published As

Publication number Publication date
IL201109A0 (en) 2010-05-17
EP2124973A1 (fr) 2009-12-02
EP2124973B1 (fr) 2015-05-27
TW200904456A (en) 2009-02-01
MY164520A (en) 2017-12-29
KR101688656B1 (ko) 2016-12-21
GT200900251A (es) 2018-10-08
AR065791A1 (es) 2009-07-01
JP2010521534A (ja) 2010-06-24
CL2008000804A1 (es) 2008-10-24
CA2681514A1 (fr) 2008-10-02
CO6230993A2 (es) 2010-12-20
BRPI0809258B8 (pt) 2021-05-25
RU2009139002A (ru) 2011-04-27
MX2009010244A (es) 2009-10-26
TN2009000387A1 (en) 2010-12-31
AU2008231847A1 (en) 2008-10-02
PE20090186A1 (es) 2009-03-20
US20080233182A1 (en) 2008-09-25
DK2124973T3 (da) 2015-06-22
NZ579852A (en) 2012-03-30
KR20100015799A (ko) 2010-02-12
CA2681514C (fr) 2016-11-08
WO2008116806A1 (fr) 2008-10-02
BRPI0809258A2 (pt) 2014-09-23
IL201109A (en) 2016-10-31
AU2008231847B2 (en) 2012-12-06
PT2124973E (pt) 2015-09-01
ES2542694T3 (es) 2015-08-10
ECSP099700A (es) 2009-11-30
PL2124973T3 (pl) 2015-10-30
BRPI0809258B1 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
MA42795A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
RU2018104725A (ru) Феноксигалогенфениламидины и их применение в качестве фунгицидов
MA31419B1 (fr) Derives de pyridine
BRPI0507495A (pt) composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
MA27946A1 (fr) Omega-carboxyaryldiphenyluree fluoro-substituee pour le traitement et la prevention de maladies et d'etats pathologiques.
NZ592382A (en) Thioamide compounds, method of making and method of using thereof
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA30024B1 (fr) 5-arylisoxazolines pour lutter contre des parasites invertebres
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
ATE533489T1 (de) Behandlung von multiplem myelom
DK1461318T3 (da) Tetrahydroquinolinanaloge som muscariniske agonister
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
MA27501A1 (fr) Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
MA54386B1 (fr) Modulateurs de trex1
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
MA35886B1 (fr) Dérivés de benzylsulfanilamide utilisés comme inhibiteurs -2 mogat
ATE555171T1 (de) Beschichtungszusammensetzung für leder oder textilmaterial
ATE110364T1 (de) Substituierte chinoline.
MA31293B1 (fr) Utilisation d'un sel de cuivre masque ou enrobe pour le traitement d'une degenerescence maculaire
DK1648904T3 (da) N-sulfonylheterocyclopyrrolalkylaminforbindelser som 5-hydroxytryptamin-6-ligander